CR10219A - Piperidinoil pirrolidinas agonistas del receptor de melanocrotina tipo 4. - Google Patents

Piperidinoil pirrolidinas agonistas del receptor de melanocrotina tipo 4.

Info

Publication number
CR10219A
CR10219A CR10219A CR10219A CR10219A CR 10219 A CR10219 A CR 10219A CR 10219 A CR10219 A CR 10219A CR 10219 A CR10219 A CR 10219A CR 10219 A CR10219 A CR 10219A
Authority
CR
Costa Rica
Prior art keywords
pirrolidines
piprolidinoil
melanocrotine
agonistas
receptor type
Prior art date
Application number
CR10219A
Other languages
English (en)
Inventor
Mark David Andrews
Alan Daniel Brown
Mark Ian Lansdell
Nicholas William Summerhill
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CR10219A publication Critical patent/CR10219A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una clase de agonistas de MCR4 de melanocortina de fórmula general (I) en la que las variables y sustituyentes son como se definen en este documento y especialmente a compuestos agonistas de MCR4 selectiva, a su uso en medicina, particularmente en el tratamiento de disfunción sexual y obesidad, a productos intermedios útiles en su síntesis y a composiciones que los contienen.
CR10219A 2006-02-23 2008-08-19 Piperidinoil pirrolidinas agonistas del receptor de melanocrotina tipo 4. CR10219A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77629506P 2006-02-23 2006-02-23
US88784007P 2007-02-02 2007-02-02

Publications (1)

Publication Number Publication Date
CR10219A true CR10219A (es) 2008-09-23

Family

ID=38169450

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10219A CR10219A (es) 2006-02-23 2008-08-19 Piperidinoil pirrolidinas agonistas del receptor de melanocrotina tipo 4.

Country Status (21)

Country Link
US (1) US8138188B2 (es)
EP (1) EP1989196B1 (es)
KR (1) KR101036981B1 (es)
AP (1) AP2008004602A0 (es)
AU (1) AU2007219236B2 (es)
BR (1) BRPI0708264A2 (es)
CA (1) CA2642922C (es)
CR (1) CR10219A (es)
DK (1) DK1989196T3 (es)
EA (1) EA200801738A1 (es)
EC (1) ECSP088688A (es)
ES (1) ES2402581T3 (es)
IL (1) IL193279A (es)
MA (1) MA30228B1 (es)
ME (1) MEP6808A (es)
MX (1) MX2008010899A (es)
NO (1) NO20083480L (es)
RS (1) RS20080371A (es)
SG (1) SG185849A1 (es)
TN (1) TNSN08337A1 (es)
WO (1) WO2007096763A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019100A1 (en) * 2007-07-19 2009-01-28 Santhera Pharmaceuticals (Schweiz) AG Substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US9603062B2 (en) 2007-11-16 2017-03-21 Qualcomm Incorporated Classifying access points using pilot identifiers
US8737295B2 (en) 2007-11-16 2014-05-27 Qualcomm Incorporated Sector identification using sector parameters signatures
US8902867B2 (en) 2007-11-16 2014-12-02 Qualcomm Incorporated Favoring access points in wireless communications
US8848656B2 (en) 2007-11-16 2014-09-30 Qualcomm Incorporated Utilizing broadcast signals to convey restricted association information
EP2103614A1 (en) * 2008-03-18 2009-09-23 Santhera Pharmaceuticals (Schweiz) AG Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators
US8588773B2 (en) 2008-08-04 2013-11-19 Qualcomm Incorporated System and method for cell search and selection in a wireless communication system
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
PE20121483A1 (es) * 2009-11-18 2012-12-02 Helsinn Healthcare Sa Composiciones para tratar nausea y vomito centralmente mediados
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
PT3333165T (pt) 2015-08-04 2019-10-29 Astellas Pharma Inc Derivado de piperazina
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
LT4161927T (lt) 2020-06-09 2024-09-25 Pfizer Inc. Spiro junginiai kaip melanokortino receptoriaus antagonistai ir jų panaudojimas
WO2023105387A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament
US12667578B2 (en) 2024-07-25 2026-06-30 Visionary Assets, Llc Cryogenic process for making cannabinoid nanoparticles and compositions made thereby
US12605394B2 (en) 2024-07-25 2026-04-21 Visionary Assets, Llc Compositions containing cannabinoid nanoparticles

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US5274143A (en) * 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors
AU697744C (en) * 1994-10-27 2002-08-22 Elanco Animal Health Ireland Limited Apolipoprotein-B synthesis inhibitors
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
IL141769A0 (en) * 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
EP2123293A3 (en) 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
ATE341327T1 (de) 2001-02-28 2006-10-15 Merck & Co Inc Acylierte piperidin-derivate als melanocortin-4- rezeptor-agonisten
CA2439152C (en) * 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
CZ2003698A3 (cs) 2001-03-22 2003-06-18 Solvay Pharmaceuticals B. V. 4,5-Dihydro-1H-pyrazolové deriváty mající CB1-antagonistickou účinnost
EP1585956A4 (en) 2001-09-24 2009-10-21 Univ Oregon Health & Science EVALUATION OF NEURONS IN THE NUCLEUS ARCUATUS FOR SCREENING ON THE ESSENTIAL CHANGING SUBSTANCES
AU2003219934A1 (en) 2002-03-06 2003-09-22 Merck And Co., Inc. Method of treatment or prevention of obesity
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
MY134457A (en) 2002-11-22 2007-12-31 Merck & Co Inc Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
GB0402492D0 (en) * 2004-02-04 2004-03-10 Pfizer Ltd Pharmaceutically active compounds
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
JP5530438B2 (ja) 2008-08-06 2014-06-25 ファイザー・リミテッド Ｍｃ４作動薬としてのジアゼピンおよびジアゾカン化合物

Also Published As

Publication number Publication date
EA200801738A1 (ru) 2008-12-30
ECSP088688A (es) 2008-10-31
KR20080095918A (ko) 2008-10-29
IL193279A0 (en) 2009-02-11
AU2007219236A1 (en) 2007-08-30
MX2008010899A (es) 2008-11-27
DK1989196T3 (da) 2013-04-15
CA2642922C (en) 2011-08-02
TNSN08337A1 (fr) 2009-12-29
WO2007096763A2 (en) 2007-08-30
AU2007219236B2 (en) 2012-06-21
IL193279A (en) 2012-12-31
ES2402581T3 (es) 2013-05-06
CA2642922A1 (en) 2007-08-30
SG185849A1 (en) 2012-12-28
WO2007096763A3 (en) 2007-10-18
NO20083480L (no) 2008-09-10
MA30228B1 (fr) 2009-02-02
EP1989196A2 (en) 2008-11-12
US8138188B2 (en) 2012-03-20
MEP6808A (xx) 2010-02-10
RS20080371A (sr) 2009-07-15
AP2008004602A0 (en) 2008-10-31
EP1989196B1 (en) 2013-02-13
BRPI0708264A2 (pt) 2011-05-24
US20090036459A1 (en) 2009-02-05
KR101036981B1 (ko) 2011-05-25
HK1126489A1 (en) 2009-09-04

Similar Documents

Publication Publication Date Title
ECSP088688A (es) Piperidinoilpirrolidinas agonistas del receptor de melanocortina tipo 4
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
ECSP066373A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
CR20110579A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
PA8779601A1 (es) Azetidinas
NI201000164A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenérgico beta 3.
GT200500119A (es) Derivados de tetraazabenzo [e] azuleno y sus analogos
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
ECSP11010880A (es) Compuestos orgánicos
UY31166A1 (es) Nuevos indazoles sustituidos, su preparación y su utilización en terapeutica
CR10192A (es) Compuestos de amido y su uso como productos farmaceuticos
ECSP088527A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
AR064692A1 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
NI200900148A (es) COMPUESTOS TRICÍCLICOS, COMPOSICIONES, Y PROCEDIMIENTOS. Caso: PC33536A
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
UY31689A1 (es) Derivados de platino-carbeno n-heterocíclico, su preparación y su aplicación en terapéutica
CO6341625A2 (es) Derivados de indol como agentes anticáncer
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones
CR11273A (es) Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica
ECSP066751A (es) Piperidinilcarbonil-pirrolidinas y su uso como agonistas de melanocortina
PE20091345A1 (es) Arilindenopirimidinas como antagonistas del receptor a2a de adenosina